Administration of stem or progenitor cells to a joint to enhance recovery from joint surgery

• US 8,343,480 B2
• Filed: 11/12/2009
• Issued: 01/01/2013
• Est. Priority Date: 11/14/2008
• Status: Active Grant

• Current Assignee: Howmedica Osteonics Corp. (Stryker Corporation)
• Original Assignee: Howmedica Osteonics Corp. (Stryker Corporation)
• Inventors: Long, Marc, Song, Lin
• Primary Examiner(s): Crouch, Deborah
• Application Number:
  US12/617,042
• Publication Number:
  US 20100150888A1
• Time in Patent Office: 1,146 Days
• Field of Search: None
• US Class Current: 424/93.2
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 35/50 Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
• CPC Class Codes: A61K 35/545 Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
• CPC Class Codes: A61K 38/1875 Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
• CPC Class Codes: A61L 2400/06 Flowable or injectable implant compositions
• CPC Class Codes: A61L 2430/24 for joint reconstruction
• CPC Class Codes: A61L 27/3834 Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
• CPC Class Codes: A61L 27/3852 Cartilage, e.g. meniscus
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis

Abstract

Disclosed are methods of enhancing recovery from joint surgery, comprising administering to the joint during surgery a composition comprising stem or progenitor cells in an amount effective to enhance recovery, and a pharmaceutically acceptable carrier.

Claims

1. A method of enhancing recovery from joint surgery, comprising administering to the joint during surgery to repair the joint a composition comprising stem or progenitor cells in an amount effective to enhance recovery, and a pharmaceutically acceptable carrier.

2. The method of claim 1, wherein said cells are autogolous progenitor or stem cells.

3. The method of claim 1, wherein said cells are allogeneic progenitor or stem cells.

4. The method of claim 1, wherein said cells comprise adult stem cells.

5. The method of claim 4, wherein said adult stem cells comprise placental-derived embryonic-like stem cells.

6. The method of claim 1, wherein said cells comprise mesenchymal stem cells.

7. The method of claim 1, wherein said cells are transfected with a gene encoding a growth factor, cytokine or extra-cellular matrix compound.

8. The method of claim 1, wherein prior to being administered, said cells are pre-challenged in an inflammatory environment.

9. The method of claim 1, wherein prior to being administered, said cells are homed to specifically bind one or more joint tissues, including synovial tissue, joint capsule, articulating cartilage, fibrocartilage (meniscus) tissue, ligament or tendon tissue.

10. The method of claim 1, wherein said carrier comprises plasma, serum, water for injection, hyaluronan, chemically modified hyaluronan, saline, phosphate buffered saline, chondroitin sulfate, glucosamine, mannosamine, proteoglycan, proteoglycan fragments, chitin, chitosan, or a combination of two or more thereof.

11. The method of claim 1, wherein said composition further comprises a gelling agent, a hydrophilic agent, a surfactant, a lipid, a phospholipid, a surface-active phospholipids, or a combination of two or more thereof.

12. The method of claim 1, wherein said composition further comprises a non-cellular therapeutic agent.

13. The method of claim 12, wherein said agent comprises a growth factor, cytokine, chemokine, hydrophilic compound, or an extracellular matrix compound.

14. The method of claim 12, where said agent is BMP -7.

15. The method of claim 1, wherein said joint is the knee, hip, shoulder, elbow, ankle, tarsal or metatarsal, wrist, spine, carpal or metacarpal, or temporal mandibular joint.

16. The method of claim 1, wherein the surgery is arthroscopic.

17. The method of claim 1, wherein the surgery is endoscopic.

18. The method of claim 1, wherein said composition is administered via injection prior to closing the joint or after the joint is closed.

19. The method of claim 1, wherein the joint is osteoarthritic.

20. The method of claim 1, wherein said composition is administered directly into the joint space.

21. The method of claim 1, wherein said composition is administered into synovial fluid.